20Med Therapeutics

🗓 Meet our CEO Michiel Lodder at #BIO2024 to learn more about our proprietary PNP platform as a leading alternative to LNPs in the delivery of #mRNA.

Great progress for our PNP-based mRNA vaccine candidate in Influenza, and 20Med continued transformation into a clinical-stage development company. ⬇   Novel preclinical results for our lead infectious disease program in influenza have been published in the peer-reviewed journal ‘Molecular Therapy: Nucleic Acids’. The in vivo data underscore the potential to develop a clearly differentiated mRNA vaccine candidate by switching the delivery vehicle to a polymer-based nanoparticle instead of an #LNP. 20Med will continue to advance the program toward clinical evaluation. Many thanks to our collaboration partners at UK Health Security Agency, who supported the preclinical work.   To review the full publication "Polymeric nanoparticle-based mRNA vaccine is protective against influenza virus infection in ferrets", please visit: https://lnkd.in/dwxE8a7m   #mRNA #vaccine #influenza #polymers #BIO24

Last week, our CSO Jaap Rip joined the mRNA-Based Therapeutics Summit and came back with a set of impressions and reflections on recent news from our sector. Enjoy reading and please chime in with your thoughts! ⬇   🔬 Improvements of the mRNA payloads and their carriers are being explored   Among the various topics discussed at the mRNA Summit, one recurring theme was the continued coevolution of the various components that mRNA-based therapeutics and vaccines are made of. At 20Med, we develop polymeric nanoparticles as a delivery vehicle for mRNA and a valuable alternative to LNPs, but likewise is the mRNA a focal point for innovation in the industry and academia. Two recent news items exemplifying this trend were i) CEPI (Coalition for Epidemic Preparedness Innovations)’s new collaboration with the Houston Methodist Research Institute on using a potentially more stable, durable and cost-effective circular mRNA, and ii), Strand Therapeutics announcement of preclinical data on a programmable mRNA that would only be activated in a specific target tissue – addressing some of the challenges to drive delivery of the mRNA into target organs by changing the nanoparticle composition.   🤝 Rising interest in polymeric solutions Meanwhile, the acceptance of polymeric alternatives for lipid nanoparticles is further increasing in the industry. With Genentech, another household name in the biopharmaceutical world, signed a cooperation agreement last week to use a polymeric nanoparticle solution as part of their R&D efforts. We believe, this should be just one of many more examples to come with Big Pharma placing alternatives bets on PNP-driven delivery strategies in addition or potentially substituting LNPs.   👍 A reminder of what vaccines are capable of Finally, a powerful reminder of the positive impact innovative vaccines can have on human health came from Scotland last week. According to a new study published by Public Health Scotland, among all women, who were fully vaccinated against human papillomavirus (HPV) at age 12 or 13 in Scotland since 2008, no one developed cervical cancer later in life. We can’t wait to see such examples being repeated many times over, with mRNA vaccines making a broad impact in human medicine.

Visiting the mRNA-based therapeutics summit today. Good to see the field advancing, not only for the mRNA technologies but also the used delivery vehicles. https://lnkd.in/dR6U-rrY

Our mission is to develop a polymeric nanoparticle platform that stands as a leading alternative to LNPs in the delivery of mRNA vaccines. Learn more about our platform's capabilities. ⬇ We keep improving our platform and designed our nanoparticles aiming for improved effectivity, (thermo)stability, lower cost of goods, and easier manufacturing than their LNP counterparts. With PNPs having their own IP position, the patent litigations hampering the LNP field can be avoided. In case you missed it, check out our latest publication in 'Biomaterials Advances' to learn all there is to know about the design principles behind 20Med's PNP platform. https://lnkd.in/dpsyQyUP Thanks to our collaborators at UMC Utrecht and University of Twente and all authors: Adriano Prado Pontes, Steffen van der Wal, Karin Roelofs, Anne Grobbink, Laura Creemers, Johan F.J. Engbersen and Jaap Rip. #mrna #vaccines #mrnavaccines #polymers #nonLNP

The pandemic has ushered in a new era of mRNA vaccinations and medicine, but improvements to each part of the mRNA platform are still needed. Our CSO, Jaap Rip, has summarized his thoughts on how polymeric nanoparticles (PNPs) can contribute to the next-generation mRNA delivery platform.

We are proud to see our most recent scientific paper online in Frontiers in Bioengineering & Biotechnology. This is just the 1st in a series of upcoming publications, which will further substantiate our claim to provide a leading #NonLNP solution to mRNA vaccine developers and other therapeutic applications in gene therapy.   🙏 👩🔬 👨🔬 A special thanks to our collaborators at UMC Utrecht and University of Medicine and Pharmacy "Iuliu Hațieganu", Cluj-Napoca and all authors:  Adriano Prado Pontes, Steffen van der Wal, Saketh Reddy Ranamalla, Karin Roelofs, Tomuta Ioan, Laura Creemers, and Jaap Rip.   Keep reading ⬇   While 20Med's development focus is on #mrna #vaccines battling infectious diseases and improving global #pandemicpreparedness, several aspects shown in this #osteoarthritis paper provide for a positive read-through on our polymeric nanoparticle (#PNP) platform's overall capabilities. Some of the highlights are:   📶 Achieving a high transfection efficiency in the target cells by optimizing the polymer-to-RNA loading ratio and dosage patterns. ⚖  The benefits of our next-generation NPs with an anionic block copolymer used in the formulation to balance the positive surface charge. 🥇 The imaging of intracellular payload release using this class of PNPs together with the visualization of reporter gene expression.   To read the full publication, please go to: https://lnkd.in/dH94xfiY  

We are thrilled to have Hugo Fry join 20Med as our new Chief Business Officer to expedite our mRNA vaccine delivery platform program. ⬇ There is a clear need for more diverse delivery technologies to unlock the full potential of #mRNA #vaccines. As an alternative to #LNPs, 20Med’s unique #PNP platform has the potential to address some of the barriers faced today by developers of #mrnavaccines. With previous roles at Sanofi, Sanofi Pasteur MSD, RQ Biotechnology Ltd., and Servier, Hugo adds substantial vaccine and infectious disease expertise to the organization and complements the existing leadership team with Michiel Lodder, CEO, and Jaap Rip, CSO, and Board members Michel BAIJOT (Chair), Jean-Paul Prieels, and Tom Schwarz. ➡ For the full press release, please go to: https://lnkd.in/dwyPDR-P Reach out via LinkedIn or email to get a more in-depth introduction to our platform's distinct features and benefits for the development of mRNA vaccines - virtual anytime or in-person during the upcoming JPMorgan Healthcare Conference Week in San Francisco #jpm2024.

We are excited to share that our CSO Jaap Rip will present at Hanson Wade Group's 2nd annual Non-Viral RNA Delivery Systems Summit in Boston this Thursday. During our presentation, we will highlight our innovative Polymeric Nanoparticle Platform, which enables the delivery of next generation vaccines and therapeutics. #polymericnanoparticles #DrugDelivery #vaccineplatform #mrnavaccines #DNAvaccines #infectiousdiseases #Hansonwade #RNATherapeutics #nonviral

Het belang van vaccins die goedkoop en snel beschikbaar zijn werd pijnlijk duidelijk tijdens de COVID-pandemie. Betaalbare en snel beschikbare vaccins zijn dan ook precies hetgeen waar University of Twente spin-off 20Med Therapeutics zich voor inzet. Met hun op RNA en DNA gebaseerde vaccins en therapieën die gemaakt zijn op basis van bioresponsieve polymeer nanodeeltjes willen ze vanuit Twente impact maken. CEO Michiel Lodder vertelt over hun technologie, impact, en toekomstplannen: "De techniek die we hebben is uniek en stelt ons in staat om breed medicijnen te ontwikkelen." Lees het artikel: https://bit.ly/3sQpcjN #medtech #spinoff #vaccin